Logo image of VVOS

VIVOS THERAPEUTICS INC (VVOS) Stock Fundamental Analysis

NASDAQ:VVOS - Nasdaq - US92859E2072 - Common Stock - Currency: USD

6.82  +0.15 (+2.25%)

After market: 6.9993 +0.18 (+2.63%)

Fundamental Rating

3

VVOS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 103 industry peers in the Health Care Providers & Services industry. VVOS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, VVOS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VVOS has reported negative net income.
In the past year VVOS has reported a negative cash flow from operations.
In the past 5 years VVOS always reported negative net income.
VVOS had a negative operating cash flow in each of the past 5 years.
VVOS Yearly Net Income VS EBIT VS OCF VS FCFVVOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

With a Return On Assets value of -99.60%, VVOS is not doing good in the industry: 95.15% of the companies in the same industry are doing better.
VVOS has a worse Return On Equity (-254.98%) than 79.61% of its industry peers.
Industry RankSector Rank
ROA -99.6%
ROE -254.98%
ROIC N/A
ROA(3y)-124.43%
ROA(5y)-96.22%
ROE(3y)-1313.92%
ROE(5y)-818.49%
ROIC(3y)N/A
ROIC(5y)N/A
VVOS Yearly ROA, ROE, ROICVVOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

VVOS's Gross Margin of 58.73% is amongst the best of the industry. VVOS outperforms 81.55% of its industry peers.
VVOS's Gross Margin has declined in the last couple of years.
VVOS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7%
GM growth 5Y-4.62%
VVOS Yearly Profit, Operating, Gross MarginsVVOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

4

2. Health

2.1 Basic Checks

VVOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VVOS has been increased compared to 1 year ago.
VVOS has more shares outstanding than it did 5 years ago.
VVOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VVOS Yearly Shares OutstandingVVOS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
VVOS Yearly Total Debt VS Total AssetsVVOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -11.53, we must say that VVOS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -11.53, VVOS is not doing good in the industry: 93.20% of the companies in the same industry are doing better.
There is no outstanding debt for VVOS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.53
ROIC/WACCN/A
WACC9.07%
VVOS Yearly LT Debt VS Equity VS FCFVVOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 0.77 indicates that VVOS may have some problems paying its short term obligations.
VVOS has a worse Current ratio (0.77) than 83.50% of its industry peers.
VVOS has a Quick Ratio of 0.77. This is a bad value and indicates that VVOS is not financially healthy enough and could expect problems in meeting its short term obligations.
VVOS has a Quick ratio of 0.77. This is in the lower half of the industry: VVOS underperforms 76.70% of its industry peers.
Industry RankSector Rank
Current Ratio 0.77
Quick Ratio 0.77
VVOS Yearly Current Assets VS Current LiabilitesVVOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 83.98% over the past year.
The Revenue has grown by 9.43% in the past year. This is quite good.
Measured over the past years, VVOS shows a small growth in Revenue. The Revenue has been growing by 5.70% on average per year.
EPS 1Y (TTM)83.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.39%
Revenue 1Y (TTM)9.43%
Revenue growth 3Y-3.81%
Revenue growth 5Y5.7%
Sales Q2Q%-11.79%

3.2 Future

VVOS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.38% yearly.
VVOS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.28% yearly.
EPS Next Y46.02%
EPS Next 2Y29.38%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0.64%
Revenue Next 2Y12.28%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VVOS Yearly Revenue VS EstimatesVVOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M
VVOS Yearly EPS VS EstimatesVVOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -5 -10 -15 -20 -25

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VVOS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VVOS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VVOS Price Earnings VS Forward Price EarningsVVOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VVOS Per share dataVVOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

VVOS's earnings are expected to grow with 29.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.38%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VVOS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIVOS THERAPEUTICS INC

NASDAQ:VVOS (7/11/2025, 8:00:02 PM)

After market: 6.9993 +0.18 (+2.63%)

6.82

+0.15 (+2.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-12 2025-08-12
Inst Owners10.54%
Inst Owner Change0%
Ins Owners1.24%
Ins Owner Change0%
Market Cap45.83M
Analysts80
Price Target4.31 (-36.8%)
Short Float %5.67%
Short Ratio1.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.1%
Min EPS beat(2)-10.29%
Max EPS beat(2)30.5%
EPS beat(4)3
Avg EPS beat(4)24.97%
Min EPS beat(4)-10.29%
Max EPS beat(4)43.98%
EPS beat(8)4
Avg EPS beat(8)4.3%
EPS beat(12)6
Avg EPS beat(12)5.79%
EPS beat(16)7
Avg EPS beat(16)-0.2%
Revenue beat(2)0
Avg Revenue beat(2)-13.02%
Min Revenue beat(2)-19.36%
Max Revenue beat(2)-6.69%
Revenue beat(4)1
Avg Revenue beat(4)-5.61%
Min Revenue beat(4)-19.36%
Max Revenue beat(4)10.4%
Revenue beat(8)1
Avg Revenue beat(8)-9.03%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-32.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-16.67%
EPS NY rev (1m)-21.26%
EPS NY rev (3m)-44.6%
Revenue NQ rev (1m)-9.84%
Revenue NQ rev (3m)-16.78%
Revenue NY rev (1m)-11.56%
Revenue NY rev (3m)-15.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.13
P/FCF N/A
P/OCF N/A
P/B 10.4
P/tB 38
EV/EBITDA N/A
EPS(TTM)-1.73
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-2.16
FCFYN/A
OCF(TTM)-2.08
OCFYN/A
SpS2.18
BVpS0.66
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.6%
ROE -254.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.73%
FCFM N/A
ROA(3y)-124.43%
ROA(5y)-96.22%
ROE(3y)-1313.92%
ROE(5y)-818.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7%
GM growth 5Y-4.62%
F-Score4
Asset Turnover1.3
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 88.07%
Cap/Sales 3.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.77
Quick Ratio 0.77
Altman-Z -11.53
F-Score4
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)121.46%
Cap/Depr(5y)141.96%
Cap/Sales(3y)5.11%
Cap/Sales(5y)6.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.39%
EPS Next Y46.02%
EPS Next 2Y29.38%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)9.43%
Revenue growth 3Y-3.81%
Revenue growth 5Y5.7%
Sales Q2Q%-11.79%
Revenue Next Year0.64%
Revenue Next 2Y12.28%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y19.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y18.06%
OCF growth 3YN/A
OCF growth 5YN/A